PARP Inhibitors in BRCA Gene-Mutated Ovarian Cancer and Beyond

@article{Banerjee2011PARPII,
  title={PARP Inhibitors in BRCA Gene-Mutated Ovarian Cancer and Beyond},
  author={S. Banerjee and S. Kaye},
  journal={Current Oncology Reports},
  year={2011},
  volume={13},
  pages={442-449}
}
  • S. Banerjee, S. Kaye
  • Published 2011
  • Medicine
  • Current Oncology Reports
  • Poly(ADP-ribose)polymerase (PARP) inhibitors are showing considerable promise for the treatment of BRCA mutation–associated ovarian and breast cancer. This approach exploits a synthetic lethal strategy to target the specific DNA repair pathway in cancers that harbor mutations in the BRCA1 or BRCA2 genes. Accumulating evidence suggests that PARP inhibitors may have a wider application in the treatment of sporadic, high-grade serous ovarian cancers and other cancers including endometrial cancer… CONTINUE READING

    Topics from this paper.

    Olaparib, PARP1 inhibitor in ovarian cancer
    • 30
    Hereditary gynaecological malignancies: advances in screening and treatment
    • 38

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 45 REFERENCES
    Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
    • 548
    • PDF
    Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
    • 4,418
    • PDF
    PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors
    • 199
    Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
    • 2,539
    Hallmarks of 'BRCAness' in sporadic cancers
    • 1,347